secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edgewise Therapeutics, Inc. (EWTX)
CIK:        0001710072
Form:       8-K
Filed at:   2023-06-22T23:59:59+00:00
Accession:  0001104659-23-073465
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 3.01, 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Director Kenneth Harrison resigns from Edgewise board; company to cure Audit Committee vacancy under Nasdaq rules
--------------------------------------------------------------------------------

- Kenneth Harrison, Ph.D. resigned from Board and all committees effective June 19, 2023; not due to disagreement.
- Resignation leaves Audit Committee with fewer than three members, violating Nasdaq Listing Rule 5605(c)(2)(A).
- Company notified Nasdaq on June 21, 2023 and will use cure period under Rule 5605(c)(4)(B) to regain compliance.
- Edgewise is evaluating board and committee membership to fill vacancy and restore compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710072/000110465923073465/0001104659-23-073465-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710072/000110465923073465/tm2319389d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-073465

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer